Abstract
This study investigated the prevalence of antibody against annexin II (A2) in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). It also explored the role of this antibody in thrombosis. Purified recombinant A2 was used in ELISA to measure the levels of IgG anti-A2 antibody in 101 APS patients, 41 SLE patients with thrombosis, 124 SLE patients without thrombosis, and 120 healthy controls. The positive rates of IgG anti-A2 antibody in APS patients and SLE patients with thrombosis were 21.8 and 26.8%, respectively. Both values are significantly higher than that in SLE patients without thrombosis (6.5%). IgG anti-A2 antibody is associated with thrombosis and/or pregnancy morbidity (P < 0.001). The data show that the levels of anti-A2 antibody are higher in APS patients and SLE patients with thrombosis. Further, the presence of this antibody is associated with thrombosis and/or pregnancy morbidity, suggesting that anti-A2 antibody may be helpful in identifying potential APS cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346:752–763. doi:10.1056/NEJMra002974
Merrill JT (2004) Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus. Lupus 13:869–876. doi:10.1191/0961203304lu2026oa
Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306. doi:10.1111/j.1538-7836.2006.01753.x
Cugno M, Cabibbe M, Galli M et al (2004) Antibodies to tissue-type plasminogen activator (t-PA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 103:2121–2126. doi:10.1182/blood-2003-07-2422
Lu CS, Horizon AA, Hwang KK et al (2005) Identification of polyclonal and monoclonal antibodies against tissue-type plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 52:4018–4027. doi:10.1002/art.21485
Emans N, Gorvel JP, Walter C et al (1993) Annexin II is a major component of fusogenic endosomal vesicles. J Cell Biol 120:1357–1369. doi:10.1083/jcb.120.6.1357
Futter CE, White IJ (2007) Annexins and endocytosis. Traffic 8:951–958. doi:10.1111/j.1600-0854.2007.00590.x
Kirshner J, Schumann D, Shively JE (2003) CEACAM1, a cell-cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis. J Biol Chem 278:50338–50345. doi:10.1074/jbc.M309115200
Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82:331–371
Dreier R, Schmid KW, Gerke V, Riehemann K (1998) Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem Cell Biol 110:137–148. doi:10.1007/s004180050275
Filipenko NR, Waisman DM (2001) The C terminus of annexin II mediates binding to F-actin. J Biol Chem 276:5310–5315. doi:10.1074/jbc.M009710200
Hajjar KA, Jacovina AT, Chacko J (1994) An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 269:21191–21197
Kassam G, Choi KS, Ghuman J et al (1998) The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 273:4790–4799. doi:10.1074/jbc.273.8.4790
Yang CD, Hwang KK, Yan W et al (2004) Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 172:5765–5773
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. doi:10.1002/art.1780400928
Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997. doi:10.1056/NEJM199504133321504
Branch DW, Khamashta MA (2003) Antiphospholipid syndrome: obstetric diagnosis, management and controversies. Obstet Gynecol 101:1333–1344. doi:10.1016/S0029-7844(03)00363-6
Bertolaccini ML, Gomez S, Pareja JF et al (2005) Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 64:1639–1643. doi:10.1136/ard.2005.035824
Tanaka Y, Ishii H, Hiraoka M et al (2007) Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: a magnetic resonance imaging study. Brain Res 1165:135–143. doi:10.1016/j.brainres.2007.06.039
Cesarman-Maus G, Rios-Luna NP, Deora AB et al (2006) Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 107:4375–4382. doi:10.1182/blood-2005-07-2636
Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (no. 30772009), the Foundation of Shanghai Science & Technical Committee (no. 07JC14070), and the Shanghai Leading Academic Discipline Project (no. T0203).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ao, W., Zheng, H., Chen, XW. et al. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int 31, 865–869 (2011). https://doi.org/10.1007/s00296-010-1379-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-010-1379-4